Page last updated: 2024-12-05

amiloride hydrochloride, anhydrous

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Amiloride hydrochloride, anhydrous is a potassium-sparing diuretic drug that is used to treat high blood pressure and edema. It works by blocking sodium channels in the kidneys, which prevents the reabsorption of sodium and water. This leads to increased excretion of sodium and water in the urine, which lowers blood pressure and reduces edema. Amiloride hydrochloride, anhydrous is often used in combination with other diuretics, such as thiazides, to enhance its effectiveness. It is also used in combination with other medications to treat heart failure. Amiloride hydrochloride, anhydrous is a synthetic drug that is available in oral and intravenous forms. It is generally well-tolerated, but side effects can include hyperkalemia, nausea, vomiting, and diarrhea. It is important to note that amiloride hydrochloride, anhydrous should not be used by people with kidney disease, hyperkalemia, or certain other medical conditions.'

amiloride hydrochloride : A hydrochloride obtained by combining amiloride with one molar equivalent of hydrochloric acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16230
CHEMBL ID540851
CHEBI ID84743
SCHEMBL ID41233
MeSH IDM0330757

Synonyms (96)

Synonym
AC-12745
MLS001148092
smr000058414
EU-0100111
amiloride hydrochloride
NCGC00180909-01
NCGC00024443-04
einecs 217-958-2
n-amidino-3,5-diamino-6-chloropyrazinecarboxamide monohydrochloride
amiloride hydrochloride, anhydrous
ccris 5959
amiloride chloride
amiloride hydrochloride anhydrous
pyrazinecarboxamide, n-amidino-3,5-diamino-6-chloro-, monohydrochloride
2016-88-8
amiloride hydrochloride hydrate
NCGC00093608-03
NCGC00093608-02
c6h8cln7o.hcl
MLS000028442 ,
SPECTRUM1500112
3,5-diamino-n-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide hydrochloride
amiloride hcl
NCGC00093608-01
anhydrous amiloride hydrochloride
A 7410
CHEMBL540851
chebi:84743 ,
3,5-diamino-6-chloro-n-(diaminomethylidene)pyrazine-2-carboxamide hydrochloride
HMS1920C03
NCGC00093608-04
7m458q65s3 ,
unii-7m458q65s3
pyrazinecarboxamide, 3,5-diamino-n-(aminoiminomethyl)-6-chloro-, monohydrochloride
NCGC00257079-01
dtxsid2024452 ,
cas-2016-88-8
tox21_303068
dtxcid504452
tox21_201386
NCGC00258937-01
A814299
n-amidino-3,5-diamino-6-chloro-pyrazinecarboxamidmonohydrochloride
nsc755847
pharmakon1600-01500112
AKOS015955970
CCG-38934
n-amidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride
amiloride * hcl
LP00111
amiloride hydrocholride
amiloride hydrochloride [mi]
amiloride hydrochloride, anhydrous [who-ip]
amiloride hydrochloride [who-dd]
amiloridi hydrochloridum [who-ip latin]
S1811
HY-B0285A
amiloride (hydrochloride)
SCHEMBL41233
KS-5339
tox21_500111
NCGC00260796-01
W-107643
amiloride monohydrochloride
3,5-diamino-n-carbamimidoyl-6-chloropyrazine-2-carboxamide hydrochloride
3,5-diamino-n-(aminoiminomethyl)-6-chloropyrazinecarboxamide hydrochloride
HB1010
OPERA_ID_212
3,5-diamino-6-chloro-n-(diaminomethylidene)pyrazine-2-carboxamide;hydrochloride
mk-870 hydrochloride
AKOS030241719
AC-32027
sr-01000000059
SR-01000000059-4
SR-01000000059-2
amiloride hydrochloride (midamor)
SW196333-4
3,5-diamino-6-chloro-n-(diaminomethylene) pyrazinecarboxamide monohydrochloride
BCP15584
Q27158032
amiloride, hydrochloride - cas 2016-88-8
amiloride hydrochloride,(s)
3,5-diamino-n-carbamimidoyl-6-chloropyrazine
-2-carboxamide hydrochloride
FS-4063
n-amido-3,5-diamino-6-chloropyrazine carboxamide hydrochloride dihydrate
3,5-diamino-6-chloro-n-(diaminomethylidene)pyrazine-2-carboxamide;hydron;chloride
1-(3,5-diamino-2-chloropyrazine-6-carbonyl)guanidine hcl
amiloride hcl anhydrous
CAA01688
HY-B0285AR
CS-0694827
amiloride (hydrochloride) (standard)
EN300-10850183
amiloride hydrochloride (3,5-diamino-n-(aminoiminomethyl)-6-chloropyrazinecarboxamide)
mfcd00058197
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
diureticAn agent that promotes the excretion of urine through its effects on kidney function.
sodium channel blockerAn agent that inhibits sodium influx through cell membranes.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (51)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency15.82030.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency39.81070.044717.8581100.0000AID485341
Chain A, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency26.58640.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency35.48135.623417.292931.6228AID2323
acid sphingomyelinaseHomo sapiens (human)Potency15.848914.125424.061339.8107AID504937
interleukin 8Homo sapiens (human)Potency66.82420.047349.480674.9780AID651758
acetylcholinesteraseHomo sapiens (human)Potency28.58840.002541.796015,848.9004AID1347395; AID1347398
glp-1 receptor, partialHomo sapiens (human)Potency8.91250.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency79.43280.100020.879379.4328AID588456
pregnane X receptorRattus norvegicus (Norway rat)Potency56.23410.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency4.95740.006038.004119,952.5996AID1159521; AID1159523
TDP1 proteinHomo sapiens (human)Potency2.61450.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency15.21170.000221.22318,912.5098AID1259243; AID1259247; AID743036; AID743042; AID743054
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency32.14870.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency54.00690.001022.650876.6163AID1224838; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency50.11870.000214.376460.0339AID588533
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency16.23570.003041.611522,387.1992AID1159552; AID1159555
pregnane X nuclear receptorHomo sapiens (human)Potency59.70850.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency10.85610.000229.305416,493.5996AID588513; AID743080
67.9K proteinVaccinia virusPotency7.07950.00018.4406100.0000AID720579
glucocerebrosidaseHomo sapiens (human)Potency14.73330.01268.156944.6684AID2101
alpha-galactosidaseHomo sapiens (human)Potency39.81074.466818.391635.4813AID2107
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02510.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency60.13040.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency34.58610.001723.839378.1014AID743083
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency28.18380.036619.637650.1187AID1466; AID2242
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency17.85330.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.00410.00419.984825.9290AID504444
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency7.94330.794321.275750.1187AID624246
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency59.06260.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency45.19830.037617.082361.1927AID1259364; AID1259388
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency20.50450.00378.618923.2809AID651784
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency40.49530.000627.21521,122.0200AID651741; AID743202; AID743219
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency0.25120.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency0.25120.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency0.25120.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2551
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency15.95410.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency0.01000.891312.067628.1838AID1487
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency28.18383.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency28.18383.548118.039535.4813AID1466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
serine/threonine-protein kinase D1 isoform 2Homo sapiens (human)IC50 (µMol)6.88480.74163.81326.8848AID1408
serine/threonine-protein kinase PLK1Homo sapiens (human)IC50 (µMol)6.62903.40008.897716.6640AID1383
Estrogen receptor betaMus musculus (house mouse)IC50 (µMol)6.88480.00176.636010.0000AID1408
Estrogen receptorMus musculus (house mouse)IC50 (µMol)6.88480.03326.195210.0000AID1408
Muscarinic receptor M1 Bos taurus (cattle)IC50 (µMol)6.88480.74163.81326.8848AID1408
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TrypsinSus scrofa (pig)AC509.29803.340016.705077.2200AID488789
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (8.33)29.6817
2010's9 (75.00)24.3611
2020's2 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.94 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]